Ann Surg Oncol

1. CHUNG AP, Dang CM, Karlan SR, Amersi FF, et al
   ASO Visual Abstract: A Prospective Study of Sentinel Node Biopsy Omission in Women Age >/= 65 with ER+ Breast Cancer.
   Ann Surg Oncol. 2024 Mar 6. doi: 10.1245/s10434-024-15137.
   

   >> Share

   
   
2. QIU M, Liang F, Xie Y, Yang H, et al
   Clinical Outcomes of Transaxillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy and Direct-to-Implant Prepectoral Breast Reconstruction: A Prospective Study of Initial 68 Procedures.
   Ann Surg Oncol. 2024;31:2777-2785.
   

   >> Share

   
   
3. WESTENEND P, Meurs C, van Bekkum S, van Rosmalen J, et al
   ASO Author Reflections: What Can Prediction Models for Upstaging of DCIS Diagnosed on Biopsy Tell Us About DCIS Surveillance Trials?
   Ann Surg Oncol. 2024;31:2272-2273.
   

   >> Share

   
   
4. EVERIDGE SA, Sun J, Teshome M, Tamirisa N, et al
   ASO Visual Abstract: Lobular Neoplasia Diagnosed by MRI-Guided Breast Biopsy-Identifying Upgrade Rate to Malignancy and Outcomes of Clinical and Surgical Management.
   Ann Surg Oncol. 2024;31:2276-2277.
   

   >> Share

   
   
5. SINGH P, Agnese D, Amin M, Barrio AV, et al
   Society of Surgical Oncology Breast Disease Site Working Group Statement on Contralateral Mastectomy: Indications, Outcomes, and Risks.
   Ann Surg Oncol. 2024;31:2212-2223.
   

   >> Share

   
   
6. RUBENSTEIN RN, Kim M, Plotsker EL, Chu JJ, et al
   Early Complications in Prepectoral Tissue Expander-Based Breast Reconstruction.
   Ann Surg Oncol. 2024;31:2766-2776.
   

   >> Share

   
   
7. QIU M, Liang F, Xie Y, Yang H, et al
   ASO Author Reflections: A Novel Technique of Transaxillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy and Direct-to-Implant Prepectoral Breast Reconstruction.
   Ann Surg Oncol. 2024;31:2791-2792.
   

   >> Share

   
   
8. POLIDORIO N, Montagna G, Sevilimedu V, Le T, et al
   Do HER2-Low Tumors Have a Distinct Clinicopathologic Phenotype?
   Ann Surg Oncol. 2024;31:2231-2243.
   

   >> Share

   
   
9. QIU M, Liang F, Xie Y, Yang H, et al
   ASO Visual Abstract: Clinical Outcomes of Transaxillary Reverse-Sequence Endoscopic Nipple-Sparing Mastectomy and Direct-to-Implant Prepectoral Breast Reconstruction-A Prospective Study of Initial 68 Procedures.
   Ann Surg Oncol. 2024;31:2794-2795.
   

   >> Share

   
   
10. EVERIDGE SA, Sun J, Teshome M, Tamirisa N, et al
    Lobular Neoplasia Diagnosed by MRI-Guided Breast Biopsy: Identifying Upgrade Rate to Malignancy and Outcomes of Clinical and Surgical Management.
    Ann Surg Oncol. 2024;31:2224-2230.
    

    >> Share

    
    

    
    BMC Cancer

11. SHITRIT IB, Wang A, Ilan K, Agassi R, et al
    Epidemiological, clinical, and pathological characteristics of invasive breast cancer in Bedouin and Jewish women in southern Israel: a retrospective comparative study.
    BMC Cancer. 2024;24:310.
    

    >> Share

    
    
12. KHANNA D, Sharma P, Budukh A, Vishwakarma R, et al
    Rural-urban disparity in cancer burden and care: findings from an Indian cancer registry.
    BMC Cancer. 2024;24:308.
    

    >> Share

    
    
13. GOH SP, Ong SC, Chan JE
    Economic evaluation of germline genetic testing for breast cancer in low- and middle-income countries: a systematic review.
    BMC Cancer. 2024;24:316.
    

    >> Share

    
    
14. KANG D, Wang C, Han Z, Zheng L, et al
    Exploration of the relationship between tumor-infiltrating lymphocyte score and histological grade in breast cancer.
    BMC Cancer. 2024;24:318.
    

    >> Share

    
    
15. MOLIERE S, Lodi M, Leblanc S, Gressel A, et al
    MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.
    BMC Cancer. 2024;24:295.
    

    >> Share

    
    
16. MESHKANI Z, Moradi N, Aboutorabi A, Farabi H, et al
    A cost-benefit analysis of genetic screening test for breast cancer in Iran.
    BMC Cancer. 2024;24:279.
    

    >> Share

    
    
17. REN J, Chen W, Zhou Y, Sun J, et al
    The novel circRNA circ_0045881 inhibits cell proliferation and invasion by targeting mir-214-3p in triple-negative breast cancer.
    BMC Cancer. 2024;24:278.
    

    >> Share

    
    

    
    Breast Cancer

18. HATTORI M, Honma N, Nagai S, Narui K, et al
    Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
    Breast Cancer. 2024 Mar 4. doi: 10.1007/s12282-024-01550.
    

    >> Share

    
    
19. OBA K, Adachi M, Kobayashi T, Takaya E, et al
    Deep learning model to predict Ki-67 expression of breast cancer using digital breast tomosynthesis.
    Breast Cancer. 2024 Mar 7. doi: 10.1007/s12282-024-01549.
    

    >> Share

    
    
20. KIDA K, Yamada A, Shimada K, Narui K, et al
    A prospective comparison study utilizing patient-reported outcomes of taxane-related peripheral neuropathy between nab-paclitaxel and standard paclitaxel in patients with breast cancer.
    Breast Cancer. 2024 Mar 8. doi: 10.1007/s12282-024-01551.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

21. MONTEIRO MR, Nunes NCC, Junior AADS, Fede ABS, et al
    Antibody-Drug Conjugates in Breast Cancer: A Comprehensive Review of How to Selectively Deliver Payloads.
    Breast Cancer (Dove Med Press). 2024;16:51-70.
    

    >> Share

    
    

    
    Breast Cancer Res

22. CASTRESANA-AGUIRRE M, Johansson A, Matikas A, Foukakis T, et al
    Clinically relevant gene signatures provide independent prognostic information in older breast cancer patients.
    Breast Cancer Res. 2024;26:38.
    

    >> Share

    
    
23. HAN Y, Otegbeye EE, Stoll C, Hardi A, et al
    How does weight gain since the age of 18 years affect breast cancer risk in later life? A meta-analysis.
    Breast Cancer Res. 2024;26:39.
    

    >> Share

    
    
24. RODON J, Demanse D, Rugo HS, Burris HA, et al
    A risk analysis of alpelisib-induced hyperglycemia in patients with advanced solid tumors and breast cancer.
    Breast Cancer Res. 2024;26:36.
    

    >> Share

    
    
25. SMOOTS SG, Schreiber AR, Jackson MM, Bagby SM, et al
    Overcoming doxorubicin resistance in triple-negative breast cancer using the class I-targeting HDAC inhibitor bocodepsin/OKI-179 to promote apoptosis.
    Breast Cancer Res. 2024;26:35.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

26. KULOTHUNGAN V, Ramamoorthy T, Sathishkumar K, Mohan R, et al
    Burden of female breast cancer in India: estimates of YLDs, YLLs, and DALYs at national and subnational levels based on the national cancer registry programme.
    Breast Cancer Res Treat. 2024 Mar 4. doi: 10.1007/s10549-024-07264.
    

    >> Share

    
    
27. PLICHTA JK, Thomas SM, Wang X, McDuff SGR, et al
    Survival among patients with untreated metastatic breast cancer: "What if I do nothing?".
    Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07265.
    

    >> Share

    
    
28. SUN H, Kang EY, Chen H, Sweeney KJ, et al
    Immunohistochemical assessment of HER2 low breast cancer: interobserver reproducibility and correlation with digital image analysis.
    Breast Cancer Res Treat. 2024 Mar 5. doi: 10.1007/s10549-024-07256.
    

    >> Share

    
    
29. CAMPBELL TM, Campbell EK, Culakova E, Blanchard LM, et al
    A whole-food, plant-based randomized controlled trial in metastatic breast cancer: weight, cardiometabolic, and hormonal outcomes.
    Breast Cancer Res Treat. 2024 Mar 6. doi: 10.1007/s10549-024-07266.
    

    >> Share

    
    
30. FINSTERBUSCH K, van Diest PJ, Focke CM
    Intertumoral heterogeneity of bifocal breast cancer: a morphological and molecular study.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07281.
    

    >> Share

    
    
31. BAYRAKCEKEN E, Yarali S, Alkan O
    Identify risk factors affecting participation of Turkish women in mammography screening for breast cancer prevention.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07296.
    

    >> Share

    
    
32. GARCIA-TORRALBA E, Perez Ramos M, Ivars Rubio A, Navarro Manzano E, et al
    Deconstructing neutrophil to lymphocyte ratio (NLR) in early breast cancer: lack of prognostic utility and biological correlates across tumor subtypes.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07286.
    

    >> Share

    
    
33. AVILA J, Leone J, Vallejo CT, Lin NU, et al
    Survival analysis of patients with brain metastases at initial breast cancer diagnosis over the last decade.
    Breast Cancer Res Treat. 2024 Mar 7. doi: 10.1007/s10549-024-07290.
    

    >> Share

    
    
34. GION M, Garcia-Mosquera JJ, Perez-Garcia JM, Peg V, et al
    Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
    Breast Cancer Res Treat. 2024 Mar 8. doi: 10.1007/s10549-024-07292.
    

    >> Share

    
    

    
    Breast J

35. SUSINI P, Marcaccini G, Giardino FR, Pozzi M, et al
    Selective Capsulotomies and Partial Capsulectomy in Implant-Based Breast Reconstruction Revision Surgery.
    Breast J. 2024;2024:9097040.
    

    >> Share

    
    

    
    Cancer

36. DELEIRE T, Mitchell JM, De La Cruz L, Isaacs C, et al
    Nonclinical factors associated with the treatment of older women with newly diagnosed low-grade ductal carcinoma in situ.
    Cancer. 2024;130:1041-1051.
    

    >> Share

    
    
37. NIERENGARTEN MB
    Cardiotoxicity of breast cancer drugs requires additional monitoring.
    Cancer. 2024;130:1013-1014.
    

    >> Share

    
    
38. NIERENGARTEN MB
    Routine estradiol testing recommended for women at high risk of breast cancer.
    Cancer. 2024;130:1014.
    

    >> Share

    
    

    
    Cancer Chemother Pharmacol

39. YUCEL KB, Aydos U, Sutcuoglu O, Kilic ACK, et al
    Visceral obesity and sarcopenia as predictors of efficacy and hematological toxicity in patients with metastatic breast cancer treated with CDK 4/6 inhibitors.
    Cancer Chemother Pharmacol. 2024 Mar 4. doi: 10.1007/s00280-024-04641.
    

    >> Share

    
    
40. ZHENG W, Peng W, Qian F, Zhang M, et al
    Vitamin D suppresses CD133+/CD44 + cancer stem cell stemness by inhibiting NF-kappaB signaling and reducing NLRP3 expression in triple-negative breast cancer.
    Cancer Chemother Pharmacol. 2024 Mar 8. doi: 10.1007/s00280-024-04660.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

41. LEE M, Kotake R, Yamauchi H
    Physical Activity and Mammographic Density in Japanese Women.
    Cancer Epidemiol Biomarkers Prev. 2024;33:365-370.
    

    >> Share

    
    
42. SIEGEL SD, Zhang Y, Lynch SM, Rowland J, et al
    A Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center.
    Cancer Epidemiol Biomarkers Prev. 2024 Mar 7. doi: 10.1158/1055-9965.EPI-23-1125
    

    >> Share

    
    

    
    Cancer Lett

43. WANG X, Deng X, Hu J, Zheng W, et al
    K48-linked deubiquitination of VGLL4 by USP15 enhances the efficacy of tumor immunotherapy in triple-negative breast cancer.
    Cancer Lett. 2024 Feb 29:216764. doi: 10.1016/j.canlet.2024.216764.
    

    >> Share

    
    

    
    Carcinogenesis

44. KIM H, Son S, Ko Y, Lim H, et al
    CYR61 confers chemoresistance by upregulating survivin expression in triple-negative breast cancer.
    Carcinogenesis. 2024 Mar 6:bgae013. doi: 10.1093.
    

    >> Share

    
    

    
    Clin Breast Cancer

45. LIAO M, Webster J, Coonrod EM, Weilbaecher KN, et al
    BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.
    Clin Breast Cancer. 2024 Feb 16:S1526-8209(24)00047.
    

    >> Share

    
    
46. MALHOTRA S, Tadros AB
    New Strategies for Locally Advanced Breast Cancer: A Review of Inflammatory Breast Cancer and Nonresponders.
    Clin Breast Cancer. 2024 Jan 21:S1526-8209(24)00009.
    

    >> Share

    
    

    
    Clin Med Insights Oncol

47. AHMADI S, Surmava S, Kvaratskhelia D, Gogolashvili A, et al
    Association Between Multiple Single Nucleotide Polymorphisms in Folate Metabolism Pathway and Breast Cancer Risk in Georgian Women: A Case-Control Study.
    Clin Med Insights Oncol. 2024;18:11795549241233693.
    

    >> Share

    
    

    
    Discov Oncol

48. VALIZADEH OSALO M, Hosseini P, Charkhian H, Soltanzadeh H, et al
    The prevalence of ADSL (rs3788579) and CYP1A2 (rs17861162) polymorphisms in female breast cancer patients in North-West Iran.
    Discov Oncol. 2024;15:59.
    

    >> Share

    
    

    
    Histopathology

49. LY A, Garcia V, Blenman KRM, Ehinger A, et al
    Training pathologists to assess stromal tumour-infiltrating lymphocytes in breast cancer synergises efforts in clinical care and scientific research.
    Histopathology. 2024 Mar 3. doi: 10.1111/his.15140.
    

    >> Share

    
    
50. LI JJX, Ni SYB, Tsang JYS, Chan WY, et al
    Neutrophil-lymphocyte ratio reflects tumour-infiltrating lymphocytes and tumour-associated macrophages and independently predicts poor outcome in breast cancers with neoadjuvant chemotherapy.
    Histopathology. 2024;84:810-821.
    

    >> Share

    
    
51. ALKHAYYAT R, Abbas A, Quinn CM, Rakha EA, et al
    Tumour 63 protein (p63) in breast pathology: biology, immunohistochemistry, diagnostic applications, and pitfalls.
    Histopathology. 2024;84:723-741.
    

    >> Share

    
    

    
    Int J Cancer

52. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    

    >> Share

    
    
53. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
    Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
    

    >> Share

    
    

    
    Int J Oncol

54. AI L, Yi N, Qiu C, Huang W, et al
    Revolutionizing breast cancer treatment: Harnessing the related mechanisms and drugs for regulated cell death (Review).
    Int J Oncol. 2024;64:46.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

55. WU VS, Khlopin M, Chadha M, Smith-Graziani DJ, et al
    Out-of-pocket cost modeling of adjuvant antiestrogen and radiation therapy after lumpectomy for early-stage breast cancer across Medicaid and Medicare plans.
    Int J Radiat Oncol Biol Phys. 2024 Mar 1:S0360-3016(24)00351.
    

    >> Share

    
    

    
    J Natl Cancer Inst

56. LEE CI, Elmore JG
    Beyond survival: a closer look at lead-time bias and disease-free intervals in mammography screening.
    J Natl Cancer Inst. 2024;116:343-344.
    

    >> Share

    
    
57. KUMAR N, Ehsan S, Banerjee S, Fernandez Perez C, et al
    The unique risk factor profile of triple negative breast cancer: a comprehensive meta-analysis.
    J Natl Cancer Inst. 2024 Mar 5:djae056. doi: 10.1093.
    

    >> Share

    
    

    
    J Pathol

58. MEYER B, Stirzaker C, Ramkomuth S, Harvey K, et al
    Detailed DNA methylation characterisation of phyllodes tumours identifies a signature of malignancy and distinguishes phyllodes from metaplastic breast carcinoma.
    J Pathol. 2024;262:480-494.
    

    >> Share

    
    

    
    Nature

59. STENZINGER A, Klauschen F
    Forget lung, breast or prostate cancer? Why we shouldn't abandon tumour names yet.
    Nature. 2024;627:38.
    

    >> Share

    
    

    
    NPJ Breast Cancer

60. PASCUAL T, Fernandez-Martinez A, Agrawal Y, Pfefferle AD, et al
    Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy.
    NPJ Breast Cancer. 2024;10:20.
    

    >> Share

    
    

    
    PLoS One

61. ABDUL REHMAN M, Tahir E, Ghulam Hussain H, Khalid A, et al
    Awareness regarding breast cancer amongst women in Pakistan: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0298275.
    

    >> Share

    
    
62. WAHLSTROM E, Audisio RA, Selvaggi G
    Aspects to consider regarding breast cancer risk in trans men: A systematic review and risk management approach.
    PLoS One. 2024;19:e0299333.
    

    >> Share

    
    
63. KESSLER LG, Comstock B, Aiello Bowles EJ, Mou J, et al
    Protocol to measure validity and reliability of colorectal, breast, cervical and lung cancer screening questions from the 2021 National Health Interview Survey: Methodology and design.
    PLoS One. 2024;19:e0297773.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

64. LAMIA KA
    Telling time in tumor samples reveals diversity of clock disruption.
    Proc Natl Acad Sci U S A. 2024;121:e2401496121.
    

    >> Share

    
    
65. TAYLOR-PHILLIPS S, Jenkinson D, Stinton C, Kunar MA, et al
    Fatigue and vigilance in medical experts detecting breast cancer.
    Proc Natl Acad Sci U S A. 2024;121:e2309576121.
    

    >> Share

    
    

    
    Radiother Oncol

66. KUBECZKO M, Jarzab M, Gabrys D, Krzywon A, et al
    Corrigendum to "Safety and feasibility of CDK4/6 inhibitors treatment combined with radiotherapy in patients with HR-positive/HER2-negative breast cancer. A systematic review and meta-analysis" [Radiother. Oncol. 187 (2023) 109839].
    Radiother Oncol. 2024;194:110188.
    

    >> Share

    
    
67. HOGSBJERG KW, Maae E, Nielsen MH, Stenbygaard L, et al
    Benefit of respiratory gating in the Danish Breast Cancer Group partial breast irradiation trial.
    Radiother Oncol. 2024 Mar 3:110195. doi: 10.1016/j.radonc.2024.110195.
    

    >> Share

    
    
68. GIMENO-MORALES M, Martinez-Monge R, Martinez-Lage A, Jablonska PA, et al
    Long-term results of intraoperative multicatheter breast implant (IOMBI) for accelerated partial breast irradiation (APBI) on early breast cancer patients.
    Radiother Oncol. 2024;194:110193.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share